REG - AstraZeneca PLC - Publication of a Prospectus

AstraZenecaAnnouncement

12/06/2019 16:45

RNS Number : 0175C
AstraZeneca PLC
12 June 2019
 


12 June 2019 16:45 BST
 
Publication of Prospectus
 
Following a routine technical update of the Company's Euro Medium Term Note ("EMTN") programme established in 2007, the following prospectus has been approved by the UK Listing Authority and is available for viewing:
 
Base Prospectus for the AstraZeneca PLC U.S. $10,000,000,000 Euro Medium Term Note Programme (the "Prospectus").
 
The last drawdown under the EMTN programme was in 2016.
 
To view the full document, please paste the following URL into the address bar of your browser.
 
http://www.rns-pdf.londonstockexchange.com/rns/0175C_1-2019-6-12.pdf
 
A copy of the above Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at:
 
http://www.morningstar.co.uk/uk/NSM
 
 
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.
 




 
Media Relations


 


 




Gonzalo Viña


 


+44 203 749 5916




Rob Skelding


Oncology


+44 203 749 5821




Rebecca Einhorn


Oncology


+1 301 518 4122




Matt Kent


BioPharma


+44 203 749 5906




Jennifer Hursit


Other


+44 203 749 5762




Christina Malmberg Hägerstrand


Sweden


+46 8 552 53 106




Michele Meixell


US


+1 302 885 2677




 


 


 




Investor Relations


 


 




Thomas Kudsk Larsen


 


+44 203 749 5712




Henry Wheeler


Oncology


+44 203 749 5797




Christer Gruvris


BioPharma (cardiovascular; metabolism)


+44 203 749 5711




Nick Stone


BioPharma (respiratory; renal)


+44 203 749 5716




Josie Afolabi


Other medicines


+44 203 749 5631




Craig Marks


Finance, fixed income


+44 7881 615 764




Jennifer Kretzmann


Corporate access, retail investors


+44 203 749 5824




US toll-free


 


+1 866 381 72 77




 
Adrian Kemp
Company Secretary
AstraZeneca PLC
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
PDICKBDBPBKDQAD